YH-002 is under clinical development by Syncromune and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I drugs for Bladder Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YH-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YH-002 is under development for the treatment of advanced solid malignancies including colon cancer, thymic cancer, prostate cancer, colorectal cancer, breast cancer and bladder cancer. The drug candidate is a tumor immune checkpoint antibody. It acts by targeting OX40. It is administered through intravenous route. It is developed based on hybridoma technology.
Syncromune is a clinical-stage biopharmaceutical business developing a novel cancer treatment that synchronises immune processes and enhances intratumoral immunotherapy to eliminate metastatic solid tumours. The company is headquartered in Fort Lauderdale
For a complete picture of YH-002’s drug-specific PTSR and LoA scores, buy the report here.